Wesper Journal

GLP-1 therapies, such as Zepbound (tirzepatide), address obstructive sleep apnea by aiding weight management, thereby reducing airway pressure and improving respiratory health. Wesper's wearable technology enhances treatment by providing continuous monitoring, allowing for timely adjustments to therapy plans. FDA’s Landmark...
Continue reading

In primary care, the integration of GLP-1 medications and Wesper's sleep technology offers a holistic approach that improves patient outcomes by enhancing metabolic health and streamlining sleep disorder management. This synergy revolutionizes healthcare delivery, promoting efficient care coordination and personalized...
Continue reading

Wesper is poised to change sleep medicine alongside GLP-1 by integrating advanced sleep monitoring technology with GLP-1 therapies, enabling comprehensive and personalized treatment for sleep apnea. This combination offers real-time treatment optimization and enhanced patient outcomes, marking a significant advancement...
Continue reading

GLP-1 Receptor Agonists and Obstructive Sleep Apnea (OSA): A New Era in Sleep Health ManagementThe approval of GLP-1 receptor agonists, such as Zepbound (tirzepatide), represents a groundbreaking development in the treatment of Obstructive Sleep Apnea (OSA). These medications not only...
Continue reading

In a landmark move, the FDA approved Zepbound (tirzepatide), the first GLP-1-based medication for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, offering hope beyond traditional CPAP therapy. It works by activating GLP-1 and GIP hormone...
Continue reading